Robert W. Baird Upgrades Envista (NYSE:NVST) to "Outperform"

Robert W. Baird upgraded shares of Envista (NYSE:NVST - Free Report) from a neutral rating to an outperform rating in a research report sent to investors on Tuesday, MarketBeat Ratings reports. They currently have $23.00 price target on the stock, up from their previous price target of $21.00.

NVST has been the topic of a number of other reports. Bank of America lowered their target price on Envista from $26.00 to $23.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Morgan Stanley set a $16.00 price objective on shares of Envista in a research note on Tuesday, April 15th. Piper Sandler lowered their target price on shares of Envista from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Needham & Company LLC reaffirmed a "hold" rating on shares of Envista in a research report on Thursday, March 6th. Finally, Wells Fargo & Company set a $19.00 price objective on Envista in a report on Saturday, March 8th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Envista currently has a consensus rating of "Hold" and an average target price of $20.23.

Envista Stock Down 0.9%

NVST traded down $0.17 during midday trading on Tuesday, hitting $18.29. The company had a trading volume of 2,560,792 shares, compared to its average volume of 2,572,119. The stock's 50 day moving average price is $16.66 and its 200 day moving average price is $18.75. Envista has a 52 week low of $14.22 and a 52 week high of $23.00. The company has a market capitalization of $3.10 billion, a price-to-earnings ratio of -2.82, a PEG ratio of 1.27 and a beta of 0.97. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44.

Envista (NYSE:NVST - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.20 by $0.04. The company had revenue of $616.90 million during the quarter, compared to the consensus estimate of $608.17 million. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the business posted $0.26 EPS. On average, research analysts anticipate that Envista will post 1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Lecap Asset Management Ltd. purchased a new stake in Envista during the fourth quarter valued at about $281,000. Hantz Financial Services Inc. increased its holdings in shares of Envista by 146.6% in the 4th quarter. Hantz Financial Services Inc. now owns 110,489 shares of the company's stock worth $2,131,000 after buying an additional 65,679 shares during the last quarter. Norges Bank purchased a new stake in Envista during the fourth quarter valued at about $38,052,000. Natixis Advisors LLC raised its holdings in shares of Envista by 1.8% during the 4th quarter. Natixis Advisors LLC now owns 106,652 shares of the company's stock valued at $2,057,000 after buying an additional 1,845 shares in the last quarter. Finally, Lightrock Netherlands B.V. bought a new stake in Envista in the 4th quarter worth approximately $5,193,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.